A Phase 1, Double-blind, Single and Multiple-Dose Study of Safety, Tolerability and Pharmacokinetics of Amilo-5MER in Healthy Volunteers
Latest Information Update: 17 May 2023
At a glance
- Drugs Amilo-5MER (Primary)
- Indications Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; First in man
- Sponsors Galmed Pharmaceuticals
Most Recent Events
- 17 May 2023 Status changed from active, no longer recruiting to completed.
- 10 Jan 2022 Status changed from recruiting to active, no longer recruiting, according to a Galmed Pharmaceuticals media release.
- 10 Jan 2022 Results presented in a Galmed Pharmaceuticals Media Release.